|Table of Contents|

Efficacy of anlotinib combined with radiofrequency ablation in the second-line treatment of advanced lung squamous cell carcinoma in the elderly

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3400-3404
Research Field:
Publishing date:

Info

Title:
Efficacy of anlotinib combined with radiofrequency ablation in the second-line treatment of advanced lung squamous cell carcinoma in the elderly
Author(s):
CUI Lin; LIU Jianjun; JIANG Yong; LIU Xingxiang; HE Xuejun
Department of Oncology,Taizhou Second People's Hospital,the Affiliated Hospital of Yangzhou University,Jiangsu Taizhou 225500,China.
Keywords:
lung squamous cell cancer; anlotinib; radiofrequency ablation
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.18.012
Abstract:
Objective:To study the clinical effect of anlotinib combined with radiofrequency ablation (RFA) in the second-line treatment of advanced lung squamous cell carcinoma in the elderly.Methods:The elderly patients with advanced lung squamous cell carcinoma who had progressed after the first-line therapy were treated with oral anlotinib and RFA of the primary lesion of the lung,while a control group with oral anlotinib alone.The clinical efficacy,side effects,quality of life and survival time of the two groups were analyzed.Results:The ORR and DCR were 42.31% and 88.46% in the observation group,34.48% and 72.41% in the control group (P＞0.05).KPS increased by 14.2 points and 4.9 points respectively（P=0.000）.PFS was (9.5±4.6) months (95%CI:5.86±10.14),(6.0±3.4) months (95%CI:4.25±7.75)(P=0.002).OS was (13.0±3.6) months (95%CI:11.34±14.66) and (10.0±2.9) months (95%CI:9.78±12.22)(P=0.000).Multiple logistic regression analysis showed that the factors affecting overall survival were RFA,clinical stage,Karnofsky performance status,and the number of effective cycles of the first-line treatment.Conclusion:The combination of RFA and anlotinib can effectively improve the local control rate of tumor,improve the quality of life and prolong the survival time of patients with advanced lung squamous cell carcinoma in the elderly after first-line therapy.The timely and effective intervention can improve the effect of clinical comprehensive treatment.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］何宏博,刘雨轩,刘东雷,等.可手术治疗的135例肺鳞癌患者预后的影响因素分析［J］.肿瘤基础与临床,2022,35（6）:503-507. HE HB，LIU YX，LIU DL，et al.Prognostic factors of 135 patients with lung squamous cell carcinoma after surgery［J］.Journal of Basic and Clinical Oncology,2022,35(6):503-507.
［3］李向南,张晓菊.肿瘤消融术在肺癌中的研究进展［J］.结核与肺部疾病杂志，2021,2（3）：256-261. LI XN,ZHANG XJ.Research progress of tumor ablation in lung cancer［J］.J Tuberc Lung Dis,2021,2（3）:256-261.
［4］HIRSCH FR,HERBST RS,GANDARA DR.EGFR tyrosine kinase inhibitors in squamous cell lung cancer［J］.Lancet Oncol,2015,16(8):872-873.
［5］LIN BY,SONG XM,YANG DW,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβ and FGFR1［J］.Gene,2018,654:77-86.
［6］HAN BH,LI K,WANG QM,et al.Effect of Anlotinib as a third-Line or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER0303 phase 3 randomized clinical trial［J］.JAMA Onco1,2018,4(11):1569-1575.
［7］SCHWARTZ LH,SEYMOUR L,LITIERE S,et al.RECIST 1.1-standardisation and disease-specific adaptations:Perspectives from the RECIST Working Group.［J］.Eur J Cancer,2016,62:138-145.
［8］崔林，陈珏，刘建军，等.放化疗结合射频消融治疗局部晚期非小细胞肺癌的临床疗效［J］.现代肿瘤医学,2018,26(06):884-887. CUI L,CHEN J,LIU JJ,et al.Chemoradiotherapy combined with radiofrequency ablation in locally advanced non-small cell lung cancer［J］.Modern Oncology,2018,26(06):884-887.
［9］A FREITES-MARTINEZ,N SANTANA,S ARIAS-SANTIAGO,et al.Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］.Actas Dermosifiliogr (Engl Ed),2021,112(1):90-92.
［10］ARTHUR H FRIENDLANDER,RONALD L ETTINGER.Karnofsky performance status scale［J］.Spec Care Dentist,2009,29(4):147-148.
［11］HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer［J］.N Engl J Med,2019,381(21):2020-2031.
［12］ WANG J,SHEN Q,SHI Q,et al.Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry［J］.J Exp Clin Cancer Res,2014,33(1):109.
［13］ 张卉，杨新杰，秦娜，等.肺鳞癌EGFR与KRAS基因突变状态分析［J］.中国肺癌杂志，2015,18（10）：621-625. ZHANG H,YANG XJ,QIN N,et al.Detection and analysis of EGFR and KRAS mutations in the patients with lung squamous cell carcinomas［J］.Chin J Lung Cancer,2015,18（10）:621-625.
［14］FESTINO L,VANELLA V,TROJANIELLO C,et al.Selecting immuno-oncology-based drug combinations what should we be considering［J］.Expert Rev Clin Pharmacol,2018,11(10):971-985.
［15］PAZ-ARES L,CIULEANU TE,COBO M,et al.First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA):an international,randomised,open-label,phase 3 trial［J］.Lancet Oncol,2021,22(2):198-211.
［16］韩宝惠，李凯，周彩存，等.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019版)［J］.中国肺癌杂志，2019，22（7）：401-412. HAN BH,LI K,ZHOU CC,et al.Chinese Expert Consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2019 edition)［J］.Chin J Lung Cancer,2019,22(7):401-412.
［17］SHEN GS,ZHENG FC,REN DF,et al.Anlotinib:a novel multi-targeting tyrosine kinase inhibitor in clinical development［J］.J Hematol Oncol,2018,11(1):120.
［18］ALFREDO PAEZ-CARPIO,FERNANDO M GOME,GEMMA ISUS OLIVE,et al.Image-guided percutaneous ablation for the treatment of lung malignancies:current state of the art［J］.Insights Imaging,2021,12(1):57.
［19］刘宝东，叶欣，范卫君，等.影像引导射频消融治疗肺部肿瘤专家共识(2018年版)［J］.中国肺癌杂志，2018,21（2）:76-88. LIU BD,YE X,FAN WJ,et al.Expert Consensus for image-guided radiofrequency ablation of pulmonary tumors (2018 version)［J］.Chin J Lung Cancer,2018,21（2）:76-88.
［20］DUPUY DE,FERNANDO HC,HILLMAN S,et al.Radiofrequency ablation of stage Ⅰa non-small cell lung cancer in medically inoperable patients;Results from the American College of Surgeons Oncology Croup 24033(Alliance)trial［J］.Cancer,2015，121(19):3491-3498.
［21］刘宝东，胡牧，刘磊，等.射频消融联合表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变非小细胞肺癌的临床价值［J］.介入放射学杂志.2018,27(11):1036-1039. LIU BD,HU M,LIU L,et al.Radiofrequency ablation combined with EGFR-TKIs for EGFR mutant non-small cell lung cancer:its clinical application［J］.J Intervent Radiol,2018,27(11):1036-1039.
［22］崔林，刘建军，姜勇，等.EGFR-TKI结合射频消融治疗晚期NSCLC时机选择分析［J］.临床医药文献电子杂志，2021，8（37）：36-39. CUI L,LIU JJ,JIANG Y,et al.Analysis of the timing of EGFR-TKI combined with radiofrequency ablation in the treatment of advanced NSCLC［J］.Electronic Journal of Clinical Medical Literature,2021,8(37):36-39.
［23］谢强，朱金秀，臧焕平，等.安罗替尼治疗表皮生长因子受体野生型老年晚期非小细胞肺癌病人的临床疗效［J］.实用老年医学,2021，35（1）：65-68. XIE Q,ZHU JX,ZANG HP,et al.Efficacy of anlotinib in the treament of elderly patients with dvanced non-small cell lung cancer with wild-type epidermal growth factor receptor［J］.Pract Geriatr,2021,35(1):65-68.

Memo

Memo:
江苏省老年健康科研课题面上项目(编号:LKM2022085);江苏省泰州市姜堰区科技专项资金扶持项目(编号：泰姜科【2019】40号)
Last Update: 1900-01-01